secwatch.observer — SEC 8-K summary
======================================

Issuer:     Quince Therapeutics, Inc. (QNCX)
CIK:        0001662774
Form:       8-K
Filed at:   2025-09-26T23:59:59+00:00
Accession:  0001193125-25-220722
Event type: debt
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01, 2.03
LLM model:  deepseek-v4-flash:cloud@v2

Quince amends EIB credit facility; min cash balance reduced to EUR 5M for Q1 2026
--------------------------------------------------------------------------------

- Minimum cash balance reduced from EUR 14.65M to EUR 5M for Jan-Mar 2026 period.
- 1% of 9% deferred interest converted to fixed rate, payable March 31, 2026.
- Amendment dated September 25, 2025 under EIB Facility originally July 24, 2020.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1662774/000119312525220722/0001193125-25-220722-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1662774/000119312525220722/d911581d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-220722

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer